Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1

Treatment with anti-PD-L1 antibodies has shown efficacy in basal-like breast cancer. In this context, identification of pre-activated immune tumors is a main goal. Here we explore mutations in PD1 and PD-L1 high-expressing tumors to identify genomic correlates associated with outcome. To do so, RNA-...

Descripción completa

Detalles Bibliográficos
Autores principales: Cimas, Francisco J., Manzano, Arancha, Baliu-Piqué, Mariona, García-Gil, Elena, Pérez-Segura, Pedro, Nagy, Ádám, Pandiella, Atanasio, Győrffy, Balázs, Ocana, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464853/
https://www.ncbi.nlm.nih.gov/pubmed/32796628
http://dx.doi.org/10.3390/cancers12082243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464853/
https://www.ncbi.nlm.nih.gov/pubmed/32796628
http://dx.doi.org/10.3390/cancers12082243

Ejemplares similares